Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 14Recruiting 7Terminated 5Active not recruiting 5Unknown 4Withdrawn 2Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gynecologic 1

Conditions

Breast Neoplasms 8Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Liposarcoma 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Endometrioid 1Brain Neoplasms 1

Interventions

Radiosurgery 7Oxaliplatin 7Docetaxel 7Paclitaxel 5Fluorouracil 5Nivolumab 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Carboplatin 4Capecitabine 4Trastuzumab 3Radiotherapy 3Radiation 3Leucovorin 3Erlotinib Hydrochloride 3Cyclophosphamide 3Cetuximab 3Bevacizumab 3spartalizumab 2sipuleucel-T 2repotrectinib 2pembrolizumab 2pazopanib 2orteronel 2fludarabine 2atezolizumab 2aldesleukin 2Temozolomide 2Surveys and Questionnaires 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasm Metastasis × Fulvestrant × Clear all
NCT04901299 2023-08-01

HER2-Signal

Massachusetts General Hospital

Phase 2 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

University of California, San Francisco

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡